Autopsy report · NCT02199938
Identification and Characterization of Molecular Markers in Musculoskeletal Tumors
Cause of deathStaffing, sites or logistics
“Principal Investigator has left the Institution”
Life of this trial
- Registered 4 years 6 months after it had already started.
- Ran for about 8 years 6 months before it stopped.
- 50 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- Balgrist University Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Soft Tissue and Bone Tumors; Sarcoma; Sarcoma of Bone; Soft Tissue Sarcoma
- Interventions
- Identification and characterization of molecular markers in musculoskeletal tumors
- Participants
- 50
- Sites
- 1
- Countries
- Switzerland
Trials that died the same way
- Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
“Principal investigator left the institution” - Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
“the Principal Investigator left the institution” - Prepectoral vs Partial Subpectoral Two-Stage Implant-Based Breast Reconstruction
“Principal Investigator left institution” - Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
“Original Principal Investigator left the institution.” - Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
“The original principal Investigator left the institution.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.